e.p.t.q. Filler: What the Jetema Product Family Includes

If a practitioner’s proposal says only “e.p.t.q.”, there are important questions to ask before an injection. e.p.t.q. is a South Korean Jetema family of hyaluronic-acid fillers, not a single product. Variants differ in firmness and intended tissue placement, and some contain lidocaine while others do not. A filler may temporarily replace local volume or soften selected folds, but choosing S100, S300 or S500 should never depend on a trendy label or social-media video.

What matters is whether the exact box, documentation and treatment goal agree. Ask about the full version and ingredients, labelled indications for the site, the thickness of your skin, previous injected materials and who will help in a complication. A well-selected product may offer modest, natural-looking change; the wrong consistency, excess volume or inappropriate placement can cause visible lumps and potentially severe harm. Doing nothing is also reasonable if you do not need a change or are not ready.

What does Jetema mean by e.p.t.q.?

Jetema’s official website describes cross-linked HA fillers S100, S300 and S500. Korean documentation for the separate e.p.t.q. Lidocaine series also lists S50. The manufacturer reports 24 mg/mL HA and 0.3% lidocaine in the referenced S100/S300/S500 lidocaine series, with 1.1 mL packs. Do not attribute those figures to every similarly branded syringe: lidocaine-free products and different package sizes exist across markets. A separate Korean table also lists 0.55 mL packs for S100, S300 and S500.

HA binds water. Chemical cross-linking turns it into a more persistent injectable gel. Jetema describes “2CM” manufacturing and a low degree of chemical modification with the cross-linking substance BDDE. This describes production technology, not proof that allergy, inflammation or vascular blockage are impossible. Even when residual ingredients meet a standard, procedure safety depends on anatomical site, technique, tissue condition and the clinician’s ability to identify trouble promptly.

The table reflects the Korean manufacturer’s product grouping, not a technique prescription. Current official instructions for the exact local-market device take precedence. Similar model numbers without lidocaine do not guarantee identical packaging or approved indications. Nor does S500 mean five times better quality than S100: these are model identifiers, not independently validated rankings.

Why the firmest filler is not necessarily the best-looking

Imagine wanting only a softer line near the mouth but being offered a material intended for stronger projection. Excess support in the wrong place may change how light falls on the face and create an unwanted heavy appearance. Conversely, a softer gel may not create the desired definition of a particular contour. It is not just about brand: a skilled clinician considers gel properties, skin thickness, tissue movement, goals and vascular anatomy.

Fine surface lines, deep folds and midface volume loss sound similar in advertising but have different causes. If the line appears chiefly during muscle movement, filler may be unhelpful. Loose or excess skin cannot be lifted simply by adding gel. Pigmentation, an inflammation mark or dryness may not improve at all with an injectable volume treatment.

“Natural” is not a property printed on an e.p.t.q. box. It depends on an appropriately conservative plan, evaluating your face at rest and in motion, and agreeing on acceptable changes. Say what you do not want, as well as what you do: for example, no change to your smile, no lip enlargement, no newly prominent cheeks. The clinician should say whether those boundaries are realistic and whether treatment makes sense at all.

How strong is the evidence for this brand?

A 2026 post-market clinical follow-up study of e.p.t.q. included 231 participants in its safety analysis. It measured fold severity, midface volume and lip fullness, as well as adverse events, over up to 24 weeks. No serious adverse events were recorded in this cohort, but 231 people cannot rule out rare serious complications. No serious adverse events were recorded in this cohort, but 231 people cannot rule out rare serious complications. Its authors cautiously suggested potential clinical usefulness and called for further randomised research. The study was funded by Jetema and several authors were connected professionally to the company. Improvement and satisfaction figures from this uncontrolled study are not independent guarantees of your result.

Jetema describes regulatory clearances in Korea, European CE marking for certain products and Brazilian authorisations in its wider portfolio. These must be verified for the exact device, generation, lot and country. CE marking is not US FDA approval; sales in numerous countries do not establish registration or availability in Armenia. Imported boxes may carry different documentation. Check traceability and legal market status before paying.

What remains uncertain? Neither the claimed low BDDE modification nor any current comparison proves that e.p.t.q. is safer than every competitor or cannot cause delayed inflammation. Nor can S500 reliably be promised to last longer than S100 in every person. Fair brand comparisons require direct trials in matching treatment sites and conditions; a universal ranking cannot be derived from gel physics or promotional claims alone. Published work through October 2026 does not yet offer sufficient comparable direct trials of the competing brands.

When to delay treatment or consider another route

If the proposed site has infection, inflamed lesions or broken skin, postpone an elective injection until evaluated and managed. Evidence about cosmetic filler safety during pregnancy and breastfeeding is insufficient; delaying is prudent. Mention known reactions to lidocaine before choosing a version—shared branding does not ensure identical ingredients.

Tell your clinician about past anaphylaxis or severe allergies, bleeding disorders and all medicines, especially those affecting bleeding. Do not stop prescribed treatment on your own. Disclose earlier fillers, other injections, inflammatory nodules, surgery or unusual changes in the area. If an older injected material is unknown, examination and perhaps imaging should come first. A new syringe cannot safely conceal an unresolved problem from an old procedure.

Wanting to erase every line, change many sites at once or guarantee not a single bruise calls for a discussion of what is achievable. It should not become pressure to accept more filler. A smaller treatment later, another method suited to a different cause, or no treatment may be better options.

What does injection feel like, and what will be visible?

After agreeing on the plan, the clinician examines and cleans the area and chooses the method allowed for the product and anatomy. Lidocaine may reduce pain, but you can still feel a puncture, pressure, stretching or sensitivity. Discuss anaesthesia and allergies. Non-sterile test syringes, home injection, needle-free “hyaluron pens” and self-administered fillers are not safe alternatives to medical care.

Pinprick marks and redness may appear in the first hours; puffiness and bruising can develop later and persist for days, occasionally weeks. Being fit for work is not the same as looking unchanged: you might wish to avoid close-up photos or explaining swelling to friends. Allow for social downtime, particularly at a conspicuous site. The immediate appearance is not the settled result.

Individual advice about skincare, exercise, makeup, sauna and pressure or massage should come from the treating clinician. Internet schedules ignore the site and any bruising. Slight asymmetry soon after a procedure may reflect swelling, the starting anatomy or volume. Discuss additional filler only after clinical review, not on the basis of one evening’s photograph.

Risks: changes that call for immediate help

Common reactions are tenderness, redness, bruising and swelling. Infection, visible nodules, migration and delayed inflammation are less common. The gravest filler complication is accidental placement inside a vessel, interrupting blood supply and potentially causing skin damage, blindness or stroke. Neither a qualified injector nor “purified hyaluronic acid” can make the risk zero.

Unusual intense pain, suddenly blanched, grey or blue-mottled skin, abrupt vision loss or neurological symptoms mean stop injecting and obtain emergency medical help immediately. Do not wait for “normal swelling” to go down. Skin-colour or vision changes call for immediate assessment even without severe pain. Increasing redness, warmth, fever or a painful lump appearing days or weeks later also require prompt examination. Do not inject dissolvers, press the site or self-prescribe antibiotics without a diagnosis.

Hyaluronidase is an enzyme clinicians sometimes use for HA filler complications or unwanted volume. Its use depends on the diagnosis and carries risks of its own. An available emergency protocol, appropriately trained staff and a route to urgent care matter far more than assurances that nothing ever goes wrong with this brand.

How to compare e.p.t.q. with Yvoire and other fillers

e.p.t.q. and Yvoire are both HA filler families, but come from different manufacturers and have different formulations. Equal HA concentration does not imply identical flexibility or durability. Yvoire has randomized studies of specified versions in nasolabial folds; published e.p.t.q. evidence includes a multi-centre post-market follow-up study, not a comparable trial directly pitting the brands against one another. Advertising durations stated in months are not comparable without matching methods and sites.

Consultation and treatment costs depend on more than the label: volume used, site, complexity, practitioner training, examination and aftercare all matter. Without verified offers there is no basis for quoting an “average Armenia price”. Ask whether review visits are included, how the product is recorded, what happens after an unsatisfactory outcome and who answers urgent calls. You may question any suggestion to inject “the entire syringe”; using its contents is not automatically a medical requirement.

Five questions that keep you in control

Ask to see the exact e.p.t.q. model, lidocaine status, original package and current instructions; check provenance and country-specific documents. Why S100, S300, S500 or a different option rather than a gentler plan? What degree of improvement is realistic, and what will remain unchanged? How obvious might bruises or swelling be over the next days, and whom can you reach afterward? Finally ask what the team does if vascular occlusion—blocked blood supply—is suspected.

Even with clear answers, you may choose more time. A product existing on the market does not mean you need it. An appropriate problem, verifiable device and freely given, calm informed consent are more valuable than a promise to look like a filtered photo instantly.